fda glp-1 warning news november 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded Drugs and Telehealth Providers New project announcement: HHS‑OIG is

From the operational side, I often see how payer documentation and compliance workflows need to adapt quickly when new drug classes expand into psychiatric care

Meanwhile, Lilly has reported positive Phase 3 topline results for its oral GLP-1 candidate Orforglipron in obesity, underscoring that the next battleground is likely to be pill-based scale-up, access, and brand-led persistence rather than efficacy alone

and reports other support from Travere Therapeutics Inc, the Doris Duke Charitable Foundation, Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly

Rybelsus, a semaglutide pill approved in 2019, has been used to treat type 2 diabetes

So that may be a change